Print Preview Area

Risk adapted chemotherapy for localised Ewings sarcoma of bone: The French EW93 study
European Journal of Cancer, 04/27/2012

Gaspar N et al. – The results showing a potential benefit of a consolidation strategy including busulfan/melphalan as compared to conventional chemotherapy needed confirmation by a randomised trial and were one of the bases of the ongoing EuroEwing99.

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Nursing Jobs
@MDLinx Career Center
View the full listing of nursing jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?

Risk adapted chemotherapy for localised Ewings sarcoma of bone: The French EW93 study European Journal of Cancer, 04/27/2012

Risk adapted chemotherapy for localised Ewings sarcoma of bone: The French EW93 study
European Journal of Cancer, 04/27/2012